Differential regulation of Krüppel-like factor family transcription factor expression in neonatal rat cardiac myocytes: effects of endothelin-1, oxidative stress and cytokines by Cullingford, T. E. et al.
1Differential regulation of Krüppel-like factor family transcription factor expression in
neonatal rat cardiac myocytes: effects of endothelin-1, oxidative stress and cytokines 
Timothy E Cullingford, Matthew J Butler, Andrew K Marshall, El Li Tham, Peter H. Sugden
and Angela Clerk*
National Heart and Lung Institute (NHLI) Division, Faculty of Medicine, Imperial College
London, Flowers Building, Armstrong Road, London SW7 2AZ, UK
Running title: Krüppel-like factors in cardiac myocytes
* Corresponding author.  NHLI Division, Faculty of Medicine, Imperial College London,
Flowers Building. (4th Floor), Armstrong Road, London SW7 2AZ, UK.  Tel.: +44 20 7594
3009; Fax: +44 20 7594 3419; E-mail: a.clerk@imperial.ac.uk.
Key words: Cardiac myocytes, endothelin-1, immediate early genes, Krüppel-like factors,
gene expression, cytokines.
2Abstract
Krüppel-like transcription factors (Klfs) modulate fundamental cell processes. 
Cardiac myocytes are terminally-differentiated, but hypertrophy in response to stimuli such
as endothelin-1.  H2O2 or cytokines promote myocyte apoptosis.  Microarray studies of
neonatal rat myocytes identified several Klfs as endothelin-1-responsive genes.  We used
quantitative PCR for further analysis of Klf expression in neonatal rat myocytes.  In response
to endothelin-1, Klf2 mRNA expression was rapidly increased (~9-fold; 15-30 min) with
later increases in expression of Klf4 and Klf6 (~5-fold; 30-60 min).  All were regulated as
immediate early genes (cycloheximide did not inhibit the increases in expression).  Klf5
expression was increased at 1-2 h (~13-fold) as a second phase response (cycloheximide
inhibited the increase).  These increases were transient and attenuated by U0126.  H2O2
increased expression of Klf2, Klf4 and Klf6, but interleukin-1$ or tumor necrosis factor "
downregulated Klf2 expression with no effect on Klf4 or Klf6.  Of the Klfs which repress
transcription, endothelin-1 rapidly downregulated expression of Klf3, Klf11 and Klf15.  The
dynamic regulation of expression of multiple Klf family members in cardiac myocytes
suggests that, as a family, they are actively involved in regulating phenotypic responses
(hypertrophy and apoptosis) to extracellular stimuli.
31. Introduction
C2H2 zinc finger transcription factors possess two cysteine and two histidine residues which
co-ordinate Zn2+ within each finger to form a conserved DNA-binding structure.  Sp1-like
proteins and Krüppel-like factors (Klfs) each have three C2H2 zinc fingers at their C-termini,
and Klfs are distinguished by a highly conserved interfinger space sequence [1].  The
seventeen mammalian Klfs which have been identified are now designated Klf1-17 [2,3],
though many have alternative names.  Several were named according to the tissues in which
they were originally shown to be enriched (e.g. Klf1 is erythroid Eklf, Klf2 is lung Lklf, Klf4
is gut Gklf, Klf5 is intestinal Iklf and Klf15 is kidney Kklf [2]).  Other Klfs are widely
expressed including Klf3 (basic Bklf), Klf6 and Klf7 (ubiquitous Uklf).  Klf9 was identified
as a basal transcription element binding (BTEB) protein, with Klf5 and Klf13 as homologues
(BTEB2 and BTEB3, respectively).  Klf10 and Klf11 were identified as early genes induced
by transforming growth factor $ and were named TIEG and TIEG2, respectively.
Klfs bind to consensus GC-rich or CACCC sequences through the three C-terminal
zinc fingers [1].  The frequency of such sequences in gene promoters, coupled with the high
sequence identity between Klf proteins in their DNA-binding domains, raises questions
relating to the specificity of any Klf for a particular promoter and potential functional
redundancy.  Nevertheless, Klfs can be clustered according to whether they act primarily as
transcriptional repressors and/or activators, and the domain structure of the N-terminal
regulatory regions.  Klf3, Klf8 and Klf12 recruit C-terminal binding proteins (CtBPs) to
repress transcription, whereas Klf9, Klf10, Klf11, Klf13 and Klf16 repress transcription
through interaction with mSIN3a [1,4].  Klf15 also represses transcription, though the
mechanism is not clear.  Klf2, Klf4, Klf5, Klf6, and Klf7 are largely transcriptional activators
4[1], but may suppress gene expression in specific circumstances (e.g. Klf5 negatively
regulates expression of Klf4 [5]).  In addition to interactions with other proteins, post-
translational modifications (e.g. phosphorylation or acetylation) regulate the transactivating
activities of different Klfs [1,6].  Globally, Klfs regulate fundamental cellular responses such
as growth, apoptosis, angiogenesis and proliferation.  For example, Klf5 overexpression is
associated with cell proliferation, whereas Klf2, Klf4 and Klf6 are more consistently
implicated in cell cycle arrest [7-9].  Klf4 and Klf5 may both promote apoptosis induced by
oxidative stress though the mechanism is unclear [9]. 
Mammalian cardiac myocytes (the contractile cells of the heart) become terminally-
differentiated shortly after birth.  Subsequent growth of the heart results from an increase in
size of individual cardiac myocytes and, in the adult, myocytes may hypertrophy in order to
maintain or increase cardiac output. This is associated with physiological and morphological
changes (increases in cell size and myofibrillogenesis) and changes in gene expression
including increased expression of immediate early genes (IEGs) and re-expression of genes
normally expressed in early development [10].   Stimuli such as endothelin-1 (ET-1), which
activate Gq protein-coupled receptors are particularly implicated in cardiac myocyte
hypertrophy, and promote both the physiological/morphological changes and the changes in
gene expression associated with the response [11].  In contrast, oxidative stresses or pro-
inflammatory cytokines may induce cardiac myocyte apoptosis [12].  Many studies have
examined the intracellular signalling pathways which are activated by various stimuli in
cardiac myocytes, and these are presumed to lead to changes in gene and protein expression
to promote hypertrophy or to facilitate myocyte death [13].  
Many Klfs are expressed in adult hearts to a degree although the cell types in which
they are expressed cannot be ascertained.  For example, Klf2 is associated with endothelial
5cells [14,15], and cardiac endothelial cells could account for expression of Klf2 in whole
heart extracts [16].  As reviewed by Haldar et al. [17], Klf13 and Klf15 are the only Klfs
which have so far been shown to play a role in cardiac myocytes.  Klf13 is highly expressed
in adult hearts [18] and is required for normal cardiac development in Xenopus [19].  Klf15 is
highly expressed in adult hearts and in cardiac myocytes [20,21].  It appears to be anti-
hypertrophic since it is downregulated during hypertrophy, and overexpression of Klf15 in
cardiac myocytes suppresses the morphological changes and changes in gene expression
induced by hypertrophic stimuli [21].  Our microarray studies highlight the dynamic changes
in expression of many genes (including Klfs) induced by H2O2 (an example of oxidative
stress) or ET-1 in cardiac myocytes over 4 h [22-25].  Here, we explore further the regulation
of Klf family members in cardiac myocytes in response to ET-1, H2O2 and pro-inflammatory
cytokines [interleukin 1$ (IL-1$) and tumour necrosis factor " (TNF")].  The dynamic
regulation of expression of multiple Klf family members suggests that, as a family, they are
actively involved in regulating phenotypic responses of cells to extracellular stimuli.
2. Materials and methods
2.1. Primary culture of neonatal rat cardiac myocytes and preparation of polysomes 
Myocytes were dissociated from the ventricles of 2- to 4-day-old Sprague-Dawley rat
hearts by an adaptation of the method of Iwaki et al. [26] as previously described [27].  Cells
were plated at 4 × 106 cells/60 mm Primaria culture dish (BD Biosciences) for 18 h in 15%
(v/v) foetal calf serum, then serum was withdrawn for 24 h before experimentation. 
Myocytes were exposed to ET-1 (100 nM),  H2O2 (0.2 mM), IL-1$ (100 ng/ml) or TNF" (10
6ng/ml) with or without pre-treatment (10 min) with inhibitors (10 :M U0126; 50 :M
LY294002; 5 :M SB203580).  Cardiac myocyte polysomes were prepared by sucrose
density centrifugation (0.8 - 1.6 M sucrose gradients; 5 ml) as previously described [25]. 
Fractions were collected by upward displacement (fraction 1 from the top of the gradient, 0.8
M sucrose; fraction 12 from the bottom of the gradient, 1.6 M sucrose) whilst monitoring
absorbance at 254 nm.  
2.2.  RNA preparation and quantitative PCR (qPCR)
Total RNA and polysome RNA (fractions 6-11 of the sucrose gradients) were
extracted and cDNA synthesized using reverse transcription as previously described [22,25]. 
qPCR was performed using a Real-Time PCR System (Model 7500, Applied Biosystems)
with optical 96-well reaction-plates (Applied Biosystems) containing (in each well) 12.5 :l
of SYBR Green Jump Start Taq Readymix (Sigma Aldrich Chemical Co.), 5 :l of
oligonucleotide primers (5 pmol each of forward and reverse primers) and 7.5 :l of cDNA
template (diluted 15-fold in water).  Primers were designed to amplify mRNA sequences
across an intron (Table 1).  qPCR analysis of glyceraldehyde 3-phosphate dehydrogenase
(Gapdh) was performed as a control and the relative quantification protocol was used.  PCR
conditions were 50/C for 2 min, 95/C for 10 min (Jump-Start Taq polymerase activation
step), followed by 40 cycles of 95/C for 15 s and 59/C for 60 s.  Following qPCR,
dissociation curve analysis was routinely performed to check for aberrant amplification
products (e.g. primer-dimers). 
2.3. Western blotting
7Cardiac myocyte nuclear extracts were prepared and Western blotting performed
essentially as described [28].  Extracts from 1.8 × 106 cells were analysed with separation of
proteins on 10% (v/v) polyacrylamide gels.  Nitrocellulose blots were probed with Klf6
rabbit polyclonal antibodies (Santa Cruz Biotechnology Inc.;  Klf6(R-173), sc-7158, 1/500
dilution).  Bands were detected and analysed by scanning densitometry as described [29]. 
3. Results
3.1 ET-1 regulates expression of multiple Klf family members in cardiac myocytes
Our microarray studies (with Affymetrix rat genome 230 2.0 arrays) of the effects of
ET-1 on cardiac myocyte gene expression over 4 h [25] identified Klfs as a family of
transcription factors which appeared to be dynamically regulated at the mRNA level.  Mining
the data specifically for Klfs, we identified rapid and transient increases in expression of
Klf2, Klf4, Klf5, Klf6, Klf9 and Klf10, with concomitant downregulation of Klf3, Klf11 and
Klf15 (Table 2).  There was no statistically significant change in expression of Klf13 or
Klf16, although Klf13 exhibited a small (non-significant; one-way ANOVA with Tukey post-
test) increase in expression over 2 - 4 h.  Klf1 (probeset 1382033_at), Klf7 (probesets
1380363_at, 1377618_at, 1384497_at) and Klf12 (probeset 1385545_at) were not
consistently called "present" with low fluorescence values and are thus expressed at minimal
levels.  We could not identify Klf8, Klf14 (Sp6) or Klf17 on the arrays.  
Using qPCR, we examined more carefully the effects of 100 nM ET-1 on Klf mRNA
expression.  Klf2 mRNA expression was significantly increased within 15 min, with maximal
expression (~9-fold relative to controls) at 30 min (Fig. 1A).  Klf4 and Klf6 mRNAs were
8also upregulated (Fig. 1, B and C), though the relative stimulation was less (~5-fold relative
to controls) and the response was delayed relative to Klf2 (maximal expression at 0.5 - 1 h). 
Klf5 mRNA was upregulated from 1 h, with maximal expression at 1.5 h (~13-fold relative to
controls) (Fig. 1D).  For these Klfs, the increase in expression was transient, with expression
of Klf2 returning to baseline within 90 min and expression of Klf4, Klf5 and Klf6 declining
to basal levels within 4 h.  The increases in expression of Klf9 and Klf10 were relatively
small (maximal expression <2-fold  at 1.5 - 2 h) although levels remained elevated over 4 - 6
h (Fig. 1, E and F).  Consistent with our microarray data, Klf3, Klf11 and Klf15 were
downregulated in response to ET-1.  Whereas the decrease in expression of Klf3 was
transient with minimal expression at ~30 min (Fig. 1G), the decrease in expression of Klf11
and Klf15 was sustained over at least 6 h (Fig. 1, H and I).  It is notable that the Klfs which
were downregulated and those with only a small increase in expression are largely associated
with transcriptional repression, whereas the Klfs with the greatest increases in expression
(Klf2, Klf4, Klf5 and Klf6) are mostly associated with transcriptional activation [1,4,6]. 
Further studies focused on this latter group.
3.2  Regulation of Klf2, Klf4, Klf5 and Klf6 by ET-1
To determine whether Klf2, Klf4, Klf5 and Klf6 mRNAs were upregulated as IEGs
(i.e. the increase in expression is regulated by pre-existing transcription factors and does not
require synthesis of new proteins), we examined the effects of 20 :M cycloheximide (to
inhibit protein synthesis).  Cycloheximide alone increased the expression of Klf2, Klf4 and
Klf6 mRNAs (Fig. 2A; probably due to activation of stress-activated signalling pathways
[30,31]), but did not inhibit the increase in expression induced by ET-1.  However, the
9increase in expression of Klf5 by ET-1 was inhibited by cycloheximide (Fig. 2B), indicating
that de novo protein synthesis is required for upregulation of Klf5 mRNA.    Thus, Klf2, Klf4
and Klf6 are regulated as IEGs in response to ET-1, whereas Klf5 is a second phase gene.
ET-1 potently activates the extracellular signal-regulated kinases 1/2 (ERK1/2) in
cardiac myocytes [32].  We used 10 :M U0126 (a selective inhibitor of the ERK1/2/5
cascades [33,34,35], though ERK5 is not significantly activated by ET-1 [24]) to determine
whether the increase in expression of Klf2, Klf4, Klf5 and Klf6 requires ERK1/2 signalling. 
U0126 minimally affected basal expression of each Klf, but partially inhibited the ET-1-
induced increase in expression of Klf2 (56 ± 4 % inhibition at 30 min; mean ± SEM, n=5),
Klf4 (43 ± 9 % inhibition at 1 h; n=4), Klf5 (72 ± 8 % inhibition at 1 h; n=4) and Klf6 (45 ±
8 % inhibition at 1 h; n=4) (Fig. 3A).  These data suggest that ERK1/2 signalling is required,
at least in part, for the upregulation of Klf2, Klf4, Klf5 and Klf6 mRNAs by ET-1. 
Signalling through phosphoinositide 3' kinase (PI3K) may increase expression of Klf2 [36],
and p38-MAPK is activated by ET-1 in cardiac myocytes [37],  so we examined the effects of
50 :M LY294002 or 5 :M SB203580 (selective inhibitors of PI3K and p38-MAPK,
respectively [34]).  Surprisingly, LY294002 increased basal expression of Klf2 and Klf4 in
cardiac myocytes and promoted further the increase in expression induced by ET-1 (Fig. 3B),
indicating that PI3K signalling is not required for the upregulation induced by ET-1 and
suggesting that basal PI3K signalling negatively regulates Klf2/Klf4 expression.  LY294002
did not affect Klf6 expression, but attenuated the increase in expression of Klf5 by ET-1. 
Since basal PI3K signalling is required for protein synthesis in cardiac myocytes [38], the
effect of LY294002 on the increase in Klf5 induced by ET-1 (which requires de novo protein
synthesis; Fig. 2B) may be a reflection of this.  SB203580 had a minimal effect on the basal
expression of Klf2, Klf4, Klf5 or Klf6, or on the increase in expression induced by ET-1 (Fig.
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3B).  It is unlikely that p38-MAPK signalling plays a significant role in the response.
3.3 Translation-state analysis of Klf2, Klf4, Klf5 and Klf6 mRNA expression
 
Given the increasing evidence for translational regulation of specific mRNAs [39,40],
we performed translation-state analysis of Klf2, Klf4, Klf5 or Klf6 mRNAs.  We used qPCR
to compare the relative levels of expression in the total RNA pool and in RNAs associated
with cardiac myocyte polysomes (prepared by sucrose density centrifugation; Fig. 4, A and
B).  Klf2, Klf4 and Klf6 mRNAs were marginally enriched in cardiac myocyte polysomes in
unstimulated cells and, following stimulation with ET-1 (1 h), the relative increase in the
polysomes was at least as great as in the total RNA pool (Fig. 4, C - E).  Klf2 was increased
5.6-fold in the polysomes (4.8-fold in total RNA), Klf4 was increased 6.4-fold (5.0-fold in
total RNA) and Klf6 was increased 4.6-fold (4.8-fold in total RNA).  Klf5 mRNA was
marginally decreased in the polysomes relative to the total pool, but the increase in
expression induced by ET-1 in the polysomes (4.3-fold) was slightly higher than in the total
pool (3.9-fold) (Fig. 4F).  We therefore expect all these Klfs to be efficiently translated into
protein.  Consistent with this, Klf6 protein (detected as bands of ~38-40 kDa on Western
blots) was increased in cardiac myocytes exposed to ET-1, with maximal expression at ~ 1 h
(Fig. 4G).  It could be argued that early genes should be efficiently translated and this may be
a property of all such genes.  However, Irs2 was upregulated as an IEG by ET-1 (no
inhibition by cycloheximide, Fig. 2A), but the mRNA was not enriched in the polysomes and
the increase in the polysomes was significantly less than that in the total RNA pool (Fig. 4H). 
Similarly, for interleukin 1 receptor-like 1 (Il1rl1), a second phase gene (upregulation was
inhibited by cycloheximide; Fig. 2B), the increase in expression in the polysomes was
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significantly less than in the total RNA pool (Fig. 4I).  It is therefore notable that Klf2, Klf4,
Klf5 and Klf6 mRNAs are efficiently recruited to the polysomes for translation into protein.
3.4  Regulation of Klf2, Klf4 and Klf6 by H2O2 and pro-inflammatory cytokines
We considered whether other stimuli also regulate expression of Klf2, Klf4 or Klf6
mRNAs.  H2O2 (0.2 mM) promotes cardiac myocyte apoptosis [41], but also stimulates
ERK1/2 (and other pathways) [42].  H2O2 stimulated a transient increase in expression of
Klf2 (Fig. 5A), but the response was less than that of ET-1 (~3.6-fold) and was delayed
(maximal increase at 1 h) (Fig. 1A).  Consistent with our previous report [23], 0.2 mM H2O2
upregulated Klf4 and Klf6 mRNAs with maximal expression (5.0-fold) from 1 h and
sustained expression over at least 6 h (Fig. 5, B and C).  We have observed a similar delay in
induction of other IEGs by H2O2 compared with ET-1 (e.g. Fos family members, unpublished
data), which may reflect the delayed time course for activation of ERK1/2 signalling
(maximal activation of ERK1/2 by ET-1 is at ~5 min [43]; maximal activation by H2O2 is at
15 - 30 min [42]).  Consistent with a role for ERK1/2 signalling, U0126 inhibited the increase
in expression of Klf2, Klf4 and Klf6 by H2O2 (Fig. 5D).  As with ET-1, SB203580 had no
effect of the response to H2O2 (Fig. 5D), whereas LY294002 enhanced the response (Fig.
5E).
In endothelial cells, Klf2 is downregulated by TNF" [15].  IL-1$ or TNF"
profoundly and rapidly (from ~1 h) downregulated Klf2 mRNA expression, a response which
was sustained over at least 6 h (Fig. 6, A and B).  Neither cytokine significantly affected the
expression of Klf4 or Klf6 (data not shown).  The decrease in expression of Klf2 in response
to IL-1$ was not affected by either SB203580 or U0126, although LY294002 (which itself
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increased expression of Klf2 mRNA, Fig. 3B) restored the baseline levels of expression (Fig.
6C).
4.  Discussion
4.1 Regulation of gene expression by Klf family members 
Many studies of individual Klfs relate to specific cells/tissues in which they are
highly expressed or for which the phenotype of a transgenic mouse suggests they may play
some role.  Thus, most studies of Klf2 focus on its regulation in lung tissue, endothelial cells
or T cells, whereas many studies of Klf4 are in gut, endothelial cells or smooth muscle cells,
and Klf5 is studied largely in gut or smooth muscle cells.  Although there are indications that
Klfs are transcriptionally regulated in these various cells (e.g. Klf2 expression is increased by
shear stress in endothelial cells [14]), and there is an indication of interplay between Klf
family members (e.g. Klf4 and Klf5 appear to operate in an antagonistic manner to regulate
cell cycle progression [8]), few studies consider the regulation and function of the Klfs as a
family.  Our data demonstrate substantial and dynamic regulation of nine Klfs by ET-1 in a
single cell type (Fig. 1) with at least three regulated as IEGs (Fig. 2A), suggesting that Klfs
potentially play a much more significant role in the phenotypic responses of more cell types
than has so far been considered. 
Klfs are defined by the high degree of homology in their C-terminal DNA-binding
domains [1,6].  It is probably not surprising, therefore, that all bind to similar consensus
DNA sequences or, with 17 family members, that such elements are relatively common in
gene promoters.  The Klfs form two principal groups of transcriptional repressors (acting
through CtBPs or mSin3a) plus a group which are primarily transcriptional activators, and it
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could be argued that the different Klf groups all do bind to similar sequences but the effect
depends on whether the Klf is an activator or repressor and, if the latter, the mode of action. 
An additional factor could be that different cells express different Klfs and interactions with
other cell-specific transcription factors may result in differential gene expression.  In cardiac
myocytes, we detected expression of at least 11 Klfs (Table 2), with regulation of several
family members from each of the activator/repressor groups by ET-1 (Fig. 1), suggesting that
(at least in this system) neither tissue specificity nor classification according to global
function is responsible for functional differences between individual Klfs.  Since there is
evidence for functional specificity in other cells [44,45], minor variations in primary and
secondary structure may be sufficient for individual Klfs to have differing affinities for
precise sequences in various gene promoters.  Expression of any individual gene may
therefore reflect the balance of Klfs expressed at any particular time in relation to the precise
DNA binding sites which can be accessed by them.
4.2 Regulation of expression of Klf2, Klf4, Klf5 and Klf6
Of the Klfs which were upregulated by ET-1, Klf2 mRNA expression increased very
rapidly and transiently (Fig. 1A), and it was regulated as an IEG (Fig. 2A).  Partial inhibition
of the response by U0126 (Fig. 3A) suggests that ERK1/2 signalling is required to some
degree.  ERK1/2 signalling was also required for upregulation of Klf2 by H2O2 (Fig. 5D).  In
contrast to endothelial cells subjected to shear stress [36], the increase in Klf2 expression by
LY294002 and enhanced response to ET-1 in the presence of LY294002 (Fig. 3B) indicated
that PI3K signalling negatively regulates Klf2 expression in cardiac myocytes.  ERK5
phosphorylation of the transcription factor MEF2 promotes Klf2 expression in other cells
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[46], but ERK5 is not significantly activated in cardiac myocytes by ET-1 [24], ERK1/2 do
not efficiently activate MEF2 [47] and inhibition of p38-MAPKs (which also phosphorylate
MEF2 [47]) by SB203580 had no effect on Klf2 expression induced by ET-1 (Fig. 3B),
suggesting that MEF2 is not the principal factor involved in this context.  Of the transcription
factors associated with the Klf2 promoter identified by Ahmed and Lingrel [48], the most
probable candidate for regulating Klf2 expression by ET-1 in our study is CREB.  CREB is
rapidly (within 5 - 10 min) phosphorylated in cardiac myocytes exposed to ET-1, a response
which is inhibited by U0126 [49].
Like Klf2, the increases in expression of Klf4 and Klf6 (Fig. 1, B and C) were
inhibited by U0126, (Figs. 3A and 5D), and both were regulated as IEGs (Fig. 2A).  Our data
are consistent with other systems in which Klf4 is regulated as an IEG by 15-deoxy-)12,14
prostaglandin J2 [50] or platelet-derived growth factor [51], and Klf6 is regulated as an IEG
by phorbol esters or serum [52,53].  However, for either Klf4 or Klf6, the potential
transcription factors or mRNA stabilisation factors which promote the increase in expression
are not known.  The increase in expression of Klf5 induced by ET-1 was inhibited by
cycloheximide (Fig. 2B), so the principal factors promoting its expression must be newly-
synthesized proteins, and the response was inhibited by U0126 (Fig. 3A), implicating
ERK1/2 signalling in the response.  These data are consistent with other studies in which
phorbol esters or fibroblast growth factor increase Klf5 expression in smooth muscle cells in
an ERK1/2-dependent manner [54] and, in fibroblasts, the increase in expression induced by
phorbol esters is inhibited by cycloheximide [55]. 
Studies of mRNA expression raise the question of whether or not changes in mRNA
expression equate to changes in protein expression.  In cardiac myocytes treated with ET-1,
translation-state analysis indicated that mRNAs for Klf2, Klf4, Klf5 and Klf6 were increased
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to a similar or greater extent in the polysomes than in the total RNA pool (Fig. 4).  Since ET-
1 also increases the global rate of protein synthesis in cardiac myocytes [56] (illustrated by
the increase in A254 profile of polysome fractions 6 - 11 with concomitant decrease of
monosome fractions 2 - 4; Fig. 4A), overall, we would predict that the rate of synthesis of
each of the Klf proteins should be increased at least in proportion to the mRNA.  Consistent
with this, we detected a significant, transient increase in expression of Klf6 protein following
stimulation with ET-1 (Fig. 4G).  Although cellular stresses such as oxidative stress can
generally inhibit translation, 0.2 mM H2O2 does not have a significant effect on global protein
synthesis over 4 h, and our microarray data indicate that Klf2, Klf4, and Klf6 are increased to
a similar extent in the polysomes as in total RNA (data not shown).
4.3 Regulating Klf-dependent gene expression in cardiac myocytes
Downregulation of Klf15 is associated with the hypertrophic response of cardiac
myocytes and may be required for hypertrophy to develop [21].  However, our data suggest
that the situation regarding Klf-mediated regulation of gene expression in cardiac myocytes is
more complex.  In cardiac myocytes exposed to ET-1, we detected a rapid decrease in
expression of mRNAs for three established repressors of gene expression (Klf3, Klf11 and
Klf15; Fig. 1, G, H and I), with simultaneous rapid increases in expression of four Klfs more
commonly associated with transcriptional activation (Klf2, Klf4, Klf5 and Klf6; Fig. 1, A -
D).  In response to ET-1, therefore, there appears to be an immediate overall switch towards
increasing Klf-directed gene expression.  However, the increases in expression of Klf2, Klf4,
Klf5 and Klf6, and decrease in expression of Klf3 were transient, with a delayed increase in
expression of Klf9 and Klf10, suggesting that the balance of Klf-regulated gene expression
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continues to change.  A similar effect was detected with H2O2, with an early increase in
expression of Klf2, Klf4, Klf5 and Klf6 and simultaneous decrease in expression of Klf3,
Klf11 and Klf15 (Fig. 5 and [23]).  In contrast, Il-1$ or TNF" promoted downregulation of
Klf2 expression (Fig. 6) with little effect on Klf4 or Klf6.  Clearly, the genes which each of
the Klfs regulates in cardiac myocytes remain to be established. 
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Figure Legends
Fig. 1.  Regulation of Klf expression by ET-1.  Cardiac myocytes were exposed to 100 nM ET-1
for the times indicated.  RNA was extracted and expression of mRNAs for different Klf family
members (A, Klf2; B, Klf4; C, Klf6; D, Klf5; E, Klf9; F, Klf10; G, Klf3; H, Klf11; I, Klf15)
analysed by qPCR.  Results are expressed relative to unstimulated controls and are means ±
S.E.M. for at least 4 independent preparations of myocytes.
Fig. 2.  Klf2, Klf4 and Klf6, but not Klf5, are upregulated as immediate early genes by ET-1.
Cardiac myocytes were unstimulated or exposed to 20 :M cycloheximide (CX, open bars), 100
nM ET-1 (black bars), or ET-1 in the presence of cycloheximide (grey bars) for 0.5 h (Klf2,
Klf4, Klf6) or 1 h (Irs2, Klf5, Il1rl1).  RNA was extracted and expression of mRNAs for Klf2,
Klf4, Klf6 and Irs2 (A, immediate early genes) or Klf5 and Il1rl1 (B, second phase genes)
analysed by qPCR.  Results are expressed relative to unstimulated controls and are means ±
S.E.M. for 3 or 4 independent preparations of myocytes.  * p<0.01  relative to ET-1 alone (one-
way ANOVA repeated measures with TUKEY post-test).
Fig. 3.  Upregulation of Klf2, Klf4, Klf6 and Klf5 by ET-1 is mediated in part through the
ERK1/2 cascade.  Cardiac myocytes were unstimulated (Control), or exposed to inhibitors alone
(10 :M U0126, 50 :M LY294002, 5 :M SB203580), to 100 nM ET-1 alone or to ET-1 in the
presence of each inhibitor for 0.5 or 1 h.  RNA was extracted and expression of mRNAs for Klf2,
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Klf4, Klf6 or Klf5 analysed by qPCR.  A, Effects of U0126 on expression of Klf mRNAs at 0.5
(Klf2) or 1 h (Klf4, Klf5, Klf6).  B, Effects of LY294002 or SB203580 on expression of Klf
mRNAs at 1 h.  Results are expressed relative to unstimulated controls and are means ± S.E.M.
for 4 or 5 independent preparations of myocytes.  * p<0.05,  # p<0.001 relative to ET-1 alone
(one-was ANOVA repeated measures with TUKEY post-test).
Fig. 4.  Translation-state analysis of Klf mRNAs.  Cardiac myocytes were unstimulated (Control)
or exposed to 100 nM ET-1 (1 h).  RNA was extracted for the total RNA pool.  Polysomes were
prepared from the same myocyte preparations using sucrose density centrifugation.  A, A254
profiles for sucrose density gradients.  B, Agarose gel electrophoresis of RNA from each fraction
with ethidium bromide staining to highlight 28S, 18S and 5S ribosomal RNAs.  Fractions 6 - 11
were pooled for polysomal RNA.  Expression of mRNAs for Klf2 (C), Klf4 (D), Klf6 (E), Klf5
(F), Irs2 (H) or Il1rl1 (I) in total RNA and polysome RNA pools was analysed by qPCR.  Results
are expressed relative to levels in total RNA from unstimulated cells and are means ± S.E.M. for
3 or 4 independent preparations of myocytes. * p<0.05, ** p<0.001 relative to Control (total
RNA); # p<0.01 relative to ET-1 (total RNA) (one-way ANOVA with TUKEY post-test).  G,
Western blotting of Klf6 protein in cardiac myocytes exposed to ET-1 for the times indicated.
A representative image is shown in the upper panel, with densitometric analysis in the lower
panel (results are means ± S.E.M. for 3 independent myocyte preparations).
Fig. 5.  H2O2 increases expression of Klf2, Klf4 and Klf6 mRNA in cardiac myocytes.  A-C,
Cardiac myocytes were exposed to 0.2 mM H2O2 for the times indicated.  RNA was extracted
and expression of mRNAs for Klf2 (A), Klf4 (B), or Klf6 (C) analysed by qPCR.  Results are
expressed relative to unstimulated controls and are means ± S.E.M. for at least 4 independent
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preparations of myocytes.  D and E, Cardiac myocytes were unstimulated (Control) or exposed
to 0.2 mM H2O2 (1 h) in the absence or presence of 5 :M SB203580 or 10 :M U0126 (D), or
50 :M LY294002 (E).  Expression of mRNAs for Klf2 (pale grey bars), Klf4 (black bars), or
Klf6 (dark grey bars) was analysed by qPCR.  Results are expressed relative to levels in
unstimulated myocytes and are means ± S.E.M. for 5 (D) or 7 (E) independent preparations of
myocytes. * p<0.001, # p<0.01 relative to H2O2 alone (one-way ANOVA with TUKEY post-
test). 
Fig. 6.  Il-1$ or TNF" promote downregulation of Klf2.  Cardiac myocytes were exposed to 100
ng/ml Il-1$ (A) or 10 ng/ml TNF" (B) for the times indicated.  RNA was extracted and
expression of Klf2 mRNA analysed by qPCR.  Results are expressed relative to unstimulated
controls and are means ± S.E.M. for at least 4 independent preparations of myocytes.  C, Cardiac
myocytes were unstimulated (Control) or exposed to 100 ng/ml Il-1$ (1 h) in the absence or
presence of 50 :M LY294002, 5 :M SB203580 or 10 :M U0126 and expression of Klf2
mRNA analysed by qPCR.  Results are expressed relative to levels in unstimulated myocytes and
are means ± S.E.M. for 3 independent preparations of myocytes. * p<0.01 relative to Il-1$ alone
(one-way ANOVA with TUKEY post-test). 
Table 1.  Primers used for QPCR validation of microarray data.  Nucleotide positions in transcripts 
are shown in parentheses for each primer.  mRNA sequences (accession numbers provided) for 
established genes were obtained from the Rat Genome Database (http://rgb.mcw.edu, viewed at 
http://www.ncbi.nlm.nih.gov/entrez). 
 
Gene Accession no. 
Size 
(bp) Forward primer Reverse primer 
     
Gapdh NM_017008 83 
GCTGGCATTGCTCTCAATGACA 
(1738-1759) 
TCCACCACCCTGTTGCTGTA 
(1801-1820) 
Il1rl1 NM_013037 84 
GTCTCAAGAGATCGTCTGAAG 
(418-438) 
CGATTCAGGGCTTCTGATAAC 
(481-501) 
Irs2 XM_573948 107 
CACCTACGCAAGCATCGACT 
(3921-3940) 
GATTCAGAGTCTTCGACGAG 
(4008-4027) 
Klf2 NM_001007684 173 
ACTTGCAGCTACACCAACTG 
(805-824) 
CTGTGACCCGTGTGCTTG 
(960-977) 
Klf3 NM_001105742 165 
TCATGTACACCAGCCACCTG 
(691-710) 
TAGTCAGTCCTCTGTGGTTC 
(837-856) 
Klf4 NM_053713 175 
TCAAGAGCTCATGCCACCGG 
(1180-1199) 
CTCGCCTGTGTGAGTTCGCA 
(1335-1354) 
Klf5 NM_053394 212 
AGCTCACCTGAGGACTCATA 
(1437-1456) 
GTGCGCAGTGCTCAGTTCT 
(1631-1649) 
Klf6 NM_031642 126 
CCTTACAGATGCTCTTGGGA 
(854-873) 
GGAGAAACACCTGTCACAGT 
(960-979) 
Klf9 NM_057211 124 
TGGCTGTGGGAAAGTCTATGG 
(954-974) 
CTCGTCCGAGCGCGAGAACT 
(1058-1077) 
Klf10 NM_031135 201 
TACTGATGTCTTCACCTACAG 
(1079-1099) 
GTACCACAAACATGACCGTG 
(1260-1279) 
Klf11 NM_001037354 165 
AACAGAATCACCTTAGCAGAG 
(1499-1519) 
AACAGCCCAGAGACCATGG 
(1645-1663) 
Klf15 NM_053536 164 
GATGAGTTGTCACGGCACC 
(1371-1389) 
CACTGCGCTCAGTTGATGG 
(1516-1534) 
 
Table 2.  Regulation of Klf isoform expression by ET-1 in cardiac myocytes (microarray 
analysis).  Cardiac myocytes were exposed to 100 nM endothelin-1 for the times indicated.  
RNA was extracted and gene expression profiling was performed using Affymetrix Rat Genome 
230 2.0 arrays.  Results are the mean expression relative to controls for n=3 (0.5 or 4 h), 6 (2 h) 
or 8 (1 h) separate sets of samples.  For multiple probesets, the average of the values is given.  
(p), predicted gene.  Klf1, Klf7 and Klf12 were not expressed at any significant level in cardiac 
myocytes.  Klf8 and Klf17 were not identified on the rat microarrays.  Klf14 is now classified as 
Sp6 [1], but we could not identify this on the rat microarrays. 
 
Time (h) Gene 
symbol 
Probeset ID 
0.5 1 2 4 
 
Significantly changed 
Klf2(p) 1376569_at, 1386041_a_at, 1394068_x_at 3.50 3.22 0.98 1.20 
Klf3 1378332_at, 1389479_at 0.88 0.65 0.60 1.08 
Klf4 1387260_at 1.98 3.60 2.69 1.79 
Klf5 1368363_at, 1394039_at 1.02 2.68 4.61 1.74 
Klf6 1387060_at, 1388986_at, 1395557_at 2.36 4.25 2.05 1.71 
Klf9 1370209_at, 1371864_at 1.03 1.22 1.61 1.27 
Klf10 1368650_at 0.77 0.85 2.14 1.50 
Klf11 1379914_at 0.89 0.63 0.56 0.48 
Klf15 1368249_at, 1381396_s_at 0.86 0.53 0.27 0.45 
 
Not significantly changed: 
Klf13 1375177_at, 1383013_at 1.07 1.10 1.58 1.67 
Klf16 1374231_at 1.06 1.12 1.47 1.11 
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